The Leeds Teaching Hospitals NHS Trust

3. Appendix 3: ALABAMA SOP, Skin Prick and Intradermal Allergy Test

Standard	Skin Prick and Intradermal Allergy
Operating	Test
Procedure	
Version No.	V4.0

Contributor	Name	Date	Signed
Written by:	Robert White Research Nurse	01.10.20	Paphier
Updated by:	Shadia Ahmed Research Fellow	10.05.22	660
Approved by:	Dr. Sinisa Savic	10.05.22	ferric from
	Consultant Immunologist		

ALABAMA SOP - Skin Prick Intradermal Allergy Test- Version 4.0 10.05.2022

	NHS Trust
Filename:	ALABAMA SOP – Skin Prick Intradermal Allergy
	Test.docx
Location of	 Clinical Immunology & Allergy, Ground Floor, Beckett Wing, SJUH
copies:	 ALABAMA Investigator Site File, Infection Research Office, Level 8 Gledhow Wing, SJUH.
	 ALABAMA Study Folder, Infection Research Network Drive
	4. ALABAMA 'PAAP SOPs' folder, shared 'N' drive, UoL

Standard Operating Procedure

Skin Prick and Intradermal Testing

The following standard operating procedure outlines how to perform a skin prick test and isapplicable to all health care professionals undertaking this role.

Skin prick (SPT) and intradermal (IDT) testing (SPT) are methods used to determine the presence of specific Immunoglobulin E (IgE) mediated reactions. SPT and IDT should be performed by an appropriately trained and competent healthcare worker who is also trained in recognition and treatment of anaphylaxis.

4. EXCLUSIONS:

SPT and IDT reactions are inhibited by antihistamines and may be inhibited by tricyclic antidepressants, tetracyclic antidepressants, topical corticosteroids and UV light treatment. Wherepossible inhibitory medication should be stopped at least 72 hours prior to testing,

Note - Patient's who are taking antihistaminergic medication, might still be suitable to continue withoral challenge

ALABAMA SOP - Skin Prick Intradermal Allergy Test- Version 4.0 10.05.2022

testing if they do not need SPT.

5. CAUTIONS:

Caution should be taken when considering SPT/IDT in pregnancy, for patients with unstableasthma or those taking beta blockers and/or ACE inhibitors.

6. EQUIPMENT:

SPT and IDT

- PPE Follow current LTHT guidelines (available on LTHT Intranet)
- Skin Marker/Pen
- Sharps bin
- Tissue Paper
- Micropore tape
- Skin test measure
- Timer (clock/watch)
- Emergency equipment available to treat anaphylaxis.
- ADULT Skin Prick & Intradermal Testing Medications (Appendix 1)

ALABAMA SOP - Skin Prick Intradermal Allergy Test- Version 4.0 10.05.2022

<u>SPT</u>

- Positive control Histamine 10mg/mL in 50% glycerol and 50% buffered 0.9% sodium chloride
- Negative control 50% glycerol and 50% buffered 0.9% sodium chloride
- Test allergen solution (Amoxicillin 20mg/ml, +/- index penicillin if different to these). *
- Individual sterile skin prick testing lancets

IDT

- Negative control-normal saline (NB positive control is not used in IDT)
- Test allergen solution (Amoxicillin 20mg/ml, +/- index penicillin if different to these). *
- Needle 30G
- Syringe 1mL
- Alcohol wipe

* Refer to **Appendix 2** for instructions for how to make testing dilutions.

7. PREPARATION:

The procedure should be undertaken in accordance with LTHT Covid-19 Coronavirus Guidelines and local infection control policy.

Perform positive ID Check, discuss procedure with patient and gain verbal consent. Check currentmedications with patient & SystmOne (see Exclusions & Cautions). Select appropriate test site free from eczema / dermatitis, the preferred site is the forearm.

8. PROCEDURE:

STP and IDT

- 1. Ensure the patient is in a comfortable sitting position or, if needle phobic, lying down. Restarm on a level surface, using a pillow if necessary.
- 2. Perform hand hygiene and don any outstanding PPE.
- 3. Remove appropriate garments to expose the testing site (typically skin of the forearm).

4. Assess the injection site for signs of inflammation, oedema, infection, and skin lesions.

9. SPT

- Ensure test site is free from body lotion and moisturisers. The Test site should be hygienically clean but does not need to be cleaned with alcohol or antiseptic. Do not rubthe area as this will create erythema.
- 6. Beginning with the positive control and ending with the test allergens (Amoxicillin, +/- index penicillin if different to these) use micropore tape to mark the test sites approximately 2.5cm apart, using first letter of allergen/control being tested (e.g. +, -, A). Place marked micropore tape on midline of forearm. Avoid the skin creases (elbow and wrist).
- 7. Place one drop of each selected allergen solution on the skin next to relevant marked site.
- 8. Using gentle pressure, push the lancet through allergen solution and into the surface layer of the skin.
- 9. Discard lancet into sharps bin.
- 10. Repeat the procedure for each allergen and the controls using a new lancet each time.
- 11. Remove surplus allergen by blotting test sites with tissue paper ensuring that no cross contamination between test sites occurs.

10.IDT (if SPT is negative and if indicated please proceed to IDT)

- 1. Attach 30G needle to 1ml syringe containing test solution / article.
- Apply gloves and clean the injection site with a swab saturated with isopropyl alcohol 70% and apply gloves.
- Remove the needle sheath and hold syringe with the dominant hand with the bevel of needle pointing up.

- 4. Beginning with the negative control use the non-dominant hand to stretch skin over the site with forefinger and thumb.
- With the syringe almost against the patient's skin, insert the needle into the skin at an angleof 10–15° and advance through the epidermis so the needle tip can be seen through the skin.
- 6. Inject medication slowly. It is not necessary to aspirate as the dermis is relatively avascular.
- 7. While injecting medication, a bleb (resembling a mosquito bite) will form.
- 8. When a 3-5mm bleb is observed withdraw the needle rapidly. Do not massage the site.
- 9. Dispose of contaminated sharps into sharps bin.
- 10. Using skin marker draw around the formed bleb.
- 11. Repeat the procedure for each allergen and the controls.

11.SPT and IDT

- 1. Advise patients not to scratch the test sites whilst waiting for the results to develop.
- 2. Ask patients to report any systemic adverse reaction (e.g. dyspnoea, dizziness).
- 3. Results should be read 15-20 minutes after the test. Measure the wheal diameter in mm. For asymmetric wheals measure the longest extent of the wheal in mm and the extent 90° to the first measurement (e.g. 3x3mm).
- 4. Record the outcome of the test in the source document.
- 5. Topical 1% hydrocortisone, oral anti-histamines or a cold compress may be given to relieve severe itch in line with a prescription.

12.INTERPRETATION:

Test sites are examined for wheal or flare after 15 - 20 minutes has elapsed. For SPT any site with a wheal diameter of \geq 3mm compared to negative control is considered a positive result. For IDT any site with a hive and associated redness and swelling outside the marked area \geq 3mm compared to the initial bleb or negative control is considered a positive result.

13.COMPLICATIONS:

Mild pruritus localised to positive test sites is the most common complication and usually resolves with no intervention.


Although SPT is a common procedure and regarded as safe, the possibility of a systemic reactionremains a possibility.

14.AFTERCARE:

If no adverse reaction has occurred, the patient is free to leave the clinic.

In case of late phase response, the patient must be instructed to call 111 or visit their local Emergency Department should they develop symptoms of dyspnoea, wheezing, dizziness orsevere pruritus.

inhibitors been taken recently?	,	Have any antihistamines, corticosteroids, anti-depressants, inhibitors been taken recently?	antipsychotics or ACE	CE First Name:		S	Surname: (Block Letters)
	Yes / No	Yes / No (Please circle)		Hospital No:	NHS No:		DOB:
If YES: Drug:		Last taken:		Consultant:	_	Ward:	Hospital:
Drug		Last taken:		(Use addressograph if available)	ph if available)		
Clinic date:						_	
Drug/Allergen		Dilution	SPT Drug/Allergen Required	Wheal Size (mm) Time:	IDT Drug/Allergen Required	Wheal Size (mm) at time zero Time:	Wheal Size (mm) at 15mins Time:
Positive Control - Histamine		10mg/mL	Prescriber Initials		Prescriber Initials		
Negative Control - Sodium Chloride	ride	0.9%	Prescriber Initials		Prescriber Initials		
AMOXICILLIN		20mg/mL	Prescriber Initials		Prescriber Initials		
BENZYLPENICILLIN		6mg/mL	Prescriber Initials		Prescriber Initials		
CO-AMOXICLAV		20mg/mL	Prescriber Initials		Prescriber Initials		
FLUCLOXACILLIN		20mg/mL	Prescriber Initials		Prescriber Initials		
Prescribed by:	Signature:		PRIN	PRINT name and contact details:	tails:		Date:
SPT administered by:	Signature:		PRIN	PRINT name and contact details:	tails:		Date:
IDT administered by:	Signature:		PRIN	PRINT name and contact details:	tails:		Date:
Compiled by:	Phili	Date:19	9 Aug 2019Approved by	مت المعادين	~~~~	Date:02 Sep 2019	2019
Skin Prick & Intradermal Testing - Medications	- Medications					Version 1.0	02/09/2019



16. Appendix 3.2: Dilution instructions

Amoxicillin		
Strength /form	ulation	250mg powder for injection
Skin prick test	Concentration	20mg/ml
	Dilution	Reconstitute the 250mg vial with 5mls water for injection to give
	instructions	approx. 50mg/ml solution.
		Withdraw 0.4mls and dilute with 0.6mls sodium chloride 0.9% to
		give a 20mg/ml solution
Intradermal	Concentration	20mg/ml
test	Dilution	As above
	instructions	
Comments		If the specified formulation is not available then the dilution
		instructions will need to be amended accordingly.
		Once reconstituted products must be used immediately.
References		Brockow, K et al. Skin test concentrations for systemically
		administered drugs an ENDA/EAACI Drug Allergy Interest Group
		position paper. Allergy. 2013 Jun; 68(6):702-12. doi:
		10.1111/all.12142. Epub 2013 Apr 25.

Amoxicillin 50)0mg	
Undiluted strength /formulation		500mg powder for injection
Skin prick test	Concentration	20mg/ml
	Dilution instructions	 Reconstitute the 500mg vial with 10mls water for injection give a 50mg/ml solution.
		2. Withdraw 4mls (200mg) and dilute with 6mls sodiumchloride 0.9% to give a 20mg/ml solution.
Intradermal	Concentration	20mg/ml
test	Dilution instructions	As above
Comments		If the specified strength and formulation is not available then the dilution instructions will need to be amended accordingly.
References		Brockow, K et al. Skin test concentrations for systemically administered drugs an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013 Jun; 68(6):702-12. doi: 10.1111/all.12142. Epub 2013 Apr 25.

Benzyl penicillin	1	
Strength /form	ulation	600mg powder for injection
Skin prick test	Concentration	6mg/ml
	Dilution	Reconstitute the 600mg vial with 10mls water for injection to give
	instructions	60mg/ml.
		Withdraw 0.1mls (6mg) and dilute this with 0.9mls sodium chloride
		0.9% to give a 6mg/ml solution
Intradermal	Concentration	6mg/ml
test	Dilution	As above
	instructions	
Comments		If the specified formulation is not available then the dilution
		instructions will need to be amended accordingly.
		Once reconstituted products must be used immediately.
References		Brockow, K et al. Skin test concentrations for systemically
		administered drugs an ENDA/EAACI Drug Allergy Interest Group
		position paper. Allergy. 2013 Jun; 68(6):702-12. doi:
		10.1111/all.12142. Epub 2013 Apr 25.

The Leeds Teaching Hospitals **NHS** NHS Trust Appendix 3.2: Dilution instructions

Co-amoxiclav		
Strength /form	ulation	1.2g, powder for solution for injection /infusion
Skin prick test	Concentration	20mg/ml
	Dilution	Reconstitute with 20mls water for injections to give 50mg /ml
	instructions	
		Withdraw 0.4mls (20mg) and dilute up to 1ml of sodium chloride
		0.9% (to give 20mgs/ml)
Intradermal	Concentration	20mg/ml
test	Dilution	As above
	instructions	
Comments		Note the concentration above (20mg/ml) only takes into account the amoxicillin component (not the clavulanic acid component)
		If the specified formulation is not available then the dilution instructions will need to be amended accordingly.
		Once reconstituted products must be used immediately
References		Brockow, K et al. Skin test concentrations for systemically
		administered drugs an ENDA/EAACI Drug Allergy Interest Group
		position paper. Allergy. 2013 Jun; 68(6):702-12. doi:
		10.1111/all.12142. Epub 2013 Apr 25.

Flucloxacillin	Flucloxacillin		
Strength /form	ulation	250mg, powder for solution for injection /infusion	
Skin prick test	Concentration	20mg/ml	
	Dilution	Reconstitute with 5mls of water for injection to give 50mgs/ml.	
	instructions	Withdraw 0.4mls (20mg). Then dilute up to 1mls with sodium	
		chloride 0.9% to give 20mgs/ml	
Intradermal	Concentration	20mg/ml	
test	Dilution	As above.	
	instructions		
Comments		If the specified formulation is not available then the dilution	
		instructions will need to be amended accordingly	
		Once reconstituted products must be used immediately	
References		Brockow, K et al. Skin test concentrations for systemically	
		administered drugs an ENDA/EAACI Drug Allergy Interest Group	
		position paper. Allergy. 2013 Jun; 68(6):702-12. doi:	
		10.1111/all.12142. Epub 2013 Apr 25.	

Flucloxacillin	Flucloxacillin 500mg		
Undiluted strength /formulation		500mg, powder for solution for injection /infusion	
Skin prick test	Concentration	20mg/ml	
	Dilution instructions	 Reconstitute the 500mg vial with 10mls water for injection to give 50mg/ml 	
		2. Withdraw 0.4mls (20mg) and dilute to 1ml with sodiumchloride 0.9% (= 20mgs/ml)	
Intradermal	Concentration	20mg/ml	
test	Dilution	As above	
	instructions		
Comments		If the specified strength and formulation is not available then the dilution instructions will need to be amended accordingly.	
References		Brockow, K et al. Skin test concentrations for systemically administered drugs an ENDA/EAACI Drug Allergy Interest Group position paper. Allergy. 2013 Jun; 68(6):702-12. doi: 10.1111/all.12142. Epub 2013 Apr 25.	

The Leeds Teaching Hospitals MHS NHS Trust 17. Appendix 3.3: Anaphylactic Reaction flowchart ANAPHYLACTIC REACTION? Airway, Breathing, Circulation, Disability, Exposure Diagnosis - Look for: Acute on set o fillness Life-threatening Airway and / or Breathing and / or Circulation problems⁴ . And usually skin changes Call for help > Lie patient flat > Raise patients legs Adrenaline² When skills and equipment available: Establish airway ٠ High flowoxygen Monitor: IV fluid challenge* Pulse Oximetry Chlorphenamine⁴ ECG Hydro cortisone 6 Blood pressure Life-threatening problems 1 swelling, hoarseness, stridor Airway: Breathing: rapid breathing, wheeze, fatigue, cyanosis, SpO2 <92%, confusion Circulation: pale, clammy, lowblood pressure, faintness, drowsy/coma 2 Adrenaline (give IM unless experienced with IV adrenaline) 3 IV fluid challenge IM doses of 1:1000 adrenaline (repeat after 5 mins if no improvement) Adult - 500 to 1000mL 500 micrograms IM (0.5mL) 500 micrograms IM (0.5mL) Adult Child - crystalloid 20mL/Kg Child > 12 years 300 micrograms IM (0.3mL) Child 6 - 12 years Stop IV colloid if this might be Child < 6 years 150 micrograms IM (0.15mL) cause of anaphylaxis 5 4 Chlorphenamine Hydrocortisone (IM or slow IV) (IM or slow IV) 200 mg Adult or child > 12 years Child 6 - 12 years Child 6 months - 6 years 10mg 100 mg 5mg 2.5mg 50mg Child < 6 months 250 micrograms/Kg 25mg Reference: https://www.resus.org.uk/anaphylaxis/emergency-treatment-of-anaphylactic-reactions/[Accessed 10 June 2019]

The Leeds Teaching Hospitals NHS Trust BIBLIOGRAPHY:

Cross, S. (2007) Understanding skin prick testing, Nursing Times: online. Available at: https://www.nursingtimes.net/understanding-skin-prick-testing/199992.article [Accessed 14 May 2019].

Heinzerling et al. (2013) The skin prick test – European standards. Clinical and Translational Allergy. 3:3.

Bousquet et al (2012) Practical guide to skin prick tests in allergy to aeroallergens. Allergy 67: 18-24: Online. Available at: <u>http://onlinelibrary.wiley.com/doi/10.1111/j.1398-9995.2011.02728.x/pdf</u> [Accessed 17 May 2019].

Toolan, J. (2008) Protocol for Skin Prick Testing. Department of Clinical Immunology and Allergy. Leeds Teaching Hosptals. Version 3.